# Gene Therapy for Achromatopsia (CNGB3)

> **NCT03001310** · PHASE1,PHASE2 · COMPLETED · sponsor: **MeiraGTx UK II Ltd** · enrollment: 23 (actual)

## Conditions studied

- Achromatopsia

## Interventions

- **BIOLOGICAL:** AAV - CNGB3

## Key facts

- **NCT ID:** NCT03001310
- **Lead sponsor:** MeiraGTx UK II Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-16
- **Primary completion:** 2019-10-25
- **Final completion:** 2019-10-25
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03001310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03001310, "Gene Therapy for Achromatopsia (CNGB3)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03001310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*